Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Cecilia BrownAcute Lymphoblastic Leukemia | February 24, 2023
No relapses occurred in patients who achieved early MRD negativity per the next-generation sequencing MRD assay.
Read More
Cecilia BrownMeeting News | February 21, 2023
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Leah SherwoodAcute Lymphoblastic Leukemia | February 15, 2023
Ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy in newly diagnosed Ph+ ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | February 9, 2023
All patients had a complete response after the first infusion, while 67% had a complete response after the second infusion.
Cecilia BrownAcute Lymphoblastic Leukemia | February 3, 2023
The efficacy of CNS prophylaxis with intrathecal chemotherapy in Ph+ ALL depends upon how many times it is given.
Cecilia BrownAcute Lymphoblastic Leukemia | February 1, 2023
Ponatinib plus hyper-CVAD led to "excellent" outcomes in patients with newly diagnosed Ph+ ALL.
Advertisement
Cecilia BrownAcute Lymphoblastic Leukemia | January 31, 2023
A chemotherapy-free regimen with ponatinib and blinatumomab led to high complete molecular response rates in Ph+ ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | January 10, 2023
A chemotherapy-free regimen led to high rates of complete remission and MRD negativity in patients with Ph+ ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | January 10, 2023
Inotuzumab ozogamicin plus hyper-CVAD with sequential blinatumomab is safe and effective for Ph-negative B-cell ALL.
Cecilia BrownAcute Lymphoblastic Leukemia | January 10, 2023
Adding blinatumomab to consolidation chemotherapy led to improved survival in MRD-negative patients with B-lineage ALL.
Leah SherwoodPrint | December 22, 2022
Although the utility of MRD in ALL has been well defined over the last decades, several questions remain.
Cecilia BrownMeeting News | December 21, 2022
Patients with ALL who underwent allogeneic HSCT in their first complete remission had a two-year OS rate of 73.9%.
Cecilia BrownAcute Lymphoblastic Leukemia | December 20, 2022
An asparaginase-containing, pediatric-inspired regimen led to an overall survival benefit in teens and young adults with ALL.
Amy Kirkwood, MScVideo Insights | December 20, 2022
Amy Kirkwood, MSc, discusses results from the randomized phase III UKALL trial during the 2022 ASH Annual Meeting.
Leah LawrenceMeeting News | December 20, 2022
There has been an improvement in the prognosis of older patients diagnosed with acute lymphoblastic leukemia.
Kerri FitzgeraldMeeting News | December 19, 2022
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 14, 2022
In the inaugural episode of The HemOnc Pulse, Chadi Nabhan, MD, MBA, FACP, hosts Hagop Kantarjian, MD, and Elias Jabbour, MD.
Chadi Nabhan, MD, MBA, FACPAcute Lymphoblastic Leukemia | December 13, 2022
Elias Jabbour, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about ALL treatment advances at ASH 2022.
Kerri FitzgeraldAcute Lymphoblastic Leukemia | December 10, 2022
The VIALE-A trial showed a sustained OS benefit in patients with AML who received venetoclax and azacitidine,
Leah SherwoodMyeloproliferative Neoplasms | December 1, 2022
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Advertisement
Advertisement
Editorial Board